Wang H, LeBert V, Li M, et al. Mannose Receptor Is Required for Optimal Induction of Vaccine-Induced T-Helper Type 17 Cells and Resistance to Blastomyces dermatitidis Infection. J Infect Dis. 2016; 213(11): 1762-6

Wang H, Li M, Hung CY, et al. MyD88 Shapes Vaccine Immunity by Extrinsically Regulating Survival of CD4+ T Cells during the Contraction Phase. PLoS Pathog. 2016; 12(8): e1005787.

Wang H, Lee TJ, Fites SJ, et al. Ligation of Dectin-2 with a novel microbial ligand promotes adjuvant activity for vaccination. PLoS Pathog. 2017 Aug 9; 13(8): e1006568.

Wang H, Li M, Lerksuthirat T, et al. The C-type lectin receptor MCL mediates vaccine-induced immunity against infection with Blastomyces dermatitidis. Infect Immun. 2015; 84(3): 635-42.

Wang H *, LeBert V *, Hung CY, et al. C- type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America. J Immunol. 2014; 192(3): 1107-19. *equal contribution.

Wang H *, Song W *, Huang G, et al. Candida albicans Zcf37, a zinc finger protein, is required for stabilization of the white state. FEBS Lett. 2011; 585(5): 797-802. *equal contribution.

Huang G *, Wang H *, Chou S, et al. Bistable expression of WOR1, a master regulator of white-opaque switching in Candida albicans. Proc Natl Acad Sci U S A. 2006; 103(34): 12813-8. *equal contribution.

METHODS AND COMPOSITIONS FOR GENERATING MODIFIED CELLS.
Publication#, WO2025096718 (pending). Priority date, 2023.

METHODS AND COMPOSITIONS FOR GENERATING CHIMERIC ANTIGEN RECEPTOR-MONOCYTES/MACROPHAGES. Publication#, WO2024026455 (pending). Priority date, 2022.

METHODS AND COMPOSITIONS FOR GENERATING MODIFIED PLURIPOTENT CELLS AND DERIVATES THEREOF. Publication#, WO2024123682A1 (pending). Priority date, 2022.

VACCINE ADJUVANT. Publication#, US12097258B2 (granted). Priority date, 2017.

Dr. Huafeng Wang is a seasoned scientist with over 20 years of experience spanning academic research and biotech innovation. Dr. Wang’s industry expertise includes small molecule, oligonucleotide, and iPSC-derived cell therapies across oncology and autoimmune indications. In his most recent biotech tenure at a pioneering cell therapy company, Shoreline Biosciences, Dr. Wang led the development of the company’s first-in-class iPSC-derived macrophage (iMAC) platform, driving it from concept to clinical-scale readiness leading to multiple preclinical programs.

He has spearheaded innovations in immune evasion, genetic armoring, and CAR engineering strategies, resulting in several U.S. patent applications. Known for his strategic vision and collaborative leadership, Dr. Wang has built and led multidisciplinary teams, managed cross-functional partnerships, and driven data-informed decision-making across all stages of preclinical development. Dr. Wang earned his PhD in molecular and cell biology from Chinese Academy of Sciences, where he conducted pioneering research in transcriptional regulation and microbial pathogenesis.

He completed his postdoctoral training in molecular and cellular immunology at the University of Wisconsin–Madison and training in drug discovery at the Calibr-Skaggs Institute for Innovative Medicines (formerly known as Calibr), a translational research unit of the Scripps Research Institute, San Diego, CA.

1

2

3

4

1

2

3

4

5

6

7